Article

Diabetes Drug Class May Cause Joint Pain, FDA Warns

Author(s):

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes may cause severe and disabling joint pain, the FDA has warned.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes may cause severe and disabling joint pain, the FDA has warned.

In response, the agency added a new Warning and Precaution about this risk to the labels of all DPP-4 inhibitors, including sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and alogliptin (Nesina).

In addition to the joint pain risk, an FDA panel previously recommended adding a warning about the potential risk for heart failure to a few of these DPP-4 inhibitors’ labels.

DPP-4 inhibitors are used alongside diet and exercise to lower blood sugar in adults with type 2 diabetes. Now, the FDA is advising health care professionals to consider the drug class as a potential cause of severe joint pain and discontinue the treatment if appropriate.

Patients already taking DPP-4 inhibitors should not stop treatment, the FDA said, but they should contact their health care professional immediately if they experience severe and persistent joint pain.

This warning stems from a search of the FDA Adverse Event Reporting System (FAERS) database and medical literature, which identified patients who started having severe joint pain from 1 day to several years after they began taking a DPP-4 inhibitor. Their symptoms were relieved usually within a month of discontinuing the drug, though some patients developed severe joint pain again when they restarted the same medication or another DPP-4 inhibitor.

In addition to joint pain, less severe side effects associated with some DPP-4 inhibitors include upper respiratory tract infection, nasopharyngitis, headache, and urinary tract infection.

The FDA urges health care professionals and patients to report any side effects from DPP-4 inhibitors to its MedWatch program.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com